Related references
Note: Only part of the references are listed.Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy
Thomas A. d'Amato et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Management of advanced colorectal cancer: state of the art
M. Saunders et al.
BRITISH JOURNAL OF CANCER (2006)
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
G Folprecht et al.
ANNALS OF ONCOLOGY (2006)
Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer
TA d'Amato et al.
ANNALS OF THORACIC SURGERY (2006)
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer:: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986
CH Köhne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer incidence and mortality in Europe, 2004
P Boyle et al.
ANNALS OF ONCOLOGY (2005)
Advances in the treatment of metastatic colorectal cancer
RM Goldberg
ONCOLOGIST (2005)
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma
RJ Parker et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Role of new agents in the treatment of colorectal cancer
CH Köhne et al.
SURGICAL ONCOLOGY-OXFORD (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy
V Loizzi et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2003)
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients
RW Holloway et al.
GYNECOLOGIC ONCOLOGY (2002)
Extreme drug resistance in primary brain tumors:: in vitro analysis of 64 resection specimens
RI Haroun et al.
JOURNAL OF NEURO-ONCOLOGY (2002)
New chemotherapy approaches in colorectal cancer
A Grothey et al.
CURRENT OPINION IN ONCOLOGY (2001)
Breast cancer survival and in vitro tumor response in the extreme drug resistance assay
RS Mehta et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard
LB Saltz et al.
ONCOLOGIST (2001)
Share Paper
